Screening

IDnow offers AML screening and monitoring

Retrieved on: 
Thursday, July 15, 2021
Financial regulation, Money laundering, Tax evasion, Terrorism, Identity verification service, Articles, AML, Screening, Verification, Crime, Business law, ComplyAdvantage

MUNICH, July 15, 2021 /PRNewswire/ -- IDnow , a leading European Platform-as-a-Service provider for identity verification, introduces automated AML (anti-money laundering) screening to its comprehensive platform.

Key Points: 
  • MUNICH, July 15, 2021 /PRNewswire/ -- IDnow , a leading European Platform-as-a-Service provider for identity verification, introduces automated AML (anti-money laundering) screening to its comprehensive platform.
  • This allows the IDnow platform to monitor thousands of AML lists concurrently and in real-time.
  • "The addition of AML screening and monitoring is further expanding the IDnow platform and marks another strategic step on our way to become the leading European platform for all identity needs."
  • As a first step, AML screening and monitoring will be offered for IDnow AutoIdent , the automated identity verification solution within IDnow's platform.

IDnow offers AML screening and monitoring

Retrieved on: 
Thursday, July 15, 2021
Financial regulation, Money laundering, Tax evasion, Terrorism, Identity verification service, Articles, AML, Screening, Verification, Crime, Business law, ComplyAdvantage

MUNICH, July 15, 2021 /PRNewswire/ -- IDnow , a leading European Platform-as-a-Service provider for identity verification, introduces automated AML (anti-money laundering) screening to its comprehensive platform.

Key Points: 
  • MUNICH, July 15, 2021 /PRNewswire/ -- IDnow , a leading European Platform-as-a-Service provider for identity verification, introduces automated AML (anti-money laundering) screening to its comprehensive platform.
  • This allows the IDnow platform to monitor thousands of AML lists concurrently and in real-time.
  • "The addition of AML screening and monitoring is further expanding the IDnow platform and marks another strategic step on our way to become the leading European platform for all identity needs."
  • As a first step, AML screening and monitoring will be offered for IDnow AutoIdent , the automated identity verification solution within IDnow's platform.

New COVID-19 Saliva Test Makes Testing Far Easier for All Ages

Retrieved on: 
Wednesday, July 14, 2021
Medical devices, Infectious diseases, Hospitals, Health, Nursing, Medical tests, Medicine, Clinical medicine, Branches of biology, COVID-19 testing, Saliva testing, Screening

View the full release here: https://www.businesswire.com/news/home/20210714005243/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210714005243/en/
    New COVID-19 saliva test makes testing far easier for all ages.
  • The screening test is performed by inserting the tip of the VSS-GP test strip into the sample, providing a positive or negative result at 20 minutes.
  • (Photo: Business Wire)
    The Intelligent Fingerprinting COVID-19 tests easy saliva sample collection makes it particularly suitable for testing more vulnerable people and children.
  • The introduction of our new COVID-19 test involved rapid design, development and manufacture within the UK over a ten-month period.

UK - National Institute for Health and Care Excellence (NICE) Issues MedTech Innovation Briefing on 'Trublood®- Prostate' for Precision Non-invasive Prostate Cancer Diagnosis Described by Experts as a 'Game Changer'

Retrieved on: 
Tuesday, July 13, 2021
Anatomy, Medicine, Prostate cancer, Clinical medicine, Histopathology, Prostate, Cancer, Screening, Prostate cancer screening, Cancer screening

Trublood-Prostate has the potential to become an innovative, minimally invasive diagnostic test for detecting prostate cancer.

Key Points: 
  • Trublood-Prostate has the potential to become an innovative, minimally invasive diagnostic test for detecting prostate cancer.
  • All experts agreed that the Trublood-Prostate has the potential to be used in addition to standard of care procedures.
  • One expert added that in the future the diagnostic test could be used together with PSA as a precision screening tool for prostate cancer.
  • Datar Cancer Genetics is a leading cancer research company specializing in non-invasive techniques for better diagnosis, treatment decisions, and management of cancer.

Thynk Health Welcomes Kim Parham as Vice President of Strategic Partnerships and Clinical Liaison

Retrieved on: 
Monday, July 12, 2021
Medicine, Lung cancer, Cancer screening, Health effects of tobacco, Medical terminology, Health, Lung cancer screening, Cancer, Screening

LEXINGTON, Ky., July 12, 2021 /PRNewswire/ -- Thynk Health, the Complete Lung Cancer Screening Solution, announced and welcomed Kim Parham as VP of Strategic Partnerships and Clinical Liaison as the company enters into a new wave of growth and business development.

Key Points: 
  • LEXINGTON, Ky., July 12, 2021 /PRNewswire/ -- Thynk Health, the Complete Lung Cancer Screening Solution, announced and welcomed Kim Parham as VP of Strategic Partnerships and Clinical Liaison as the company enters into a new wave of growth and business development.
  • She is excited to be joining the Thynk Health team offering technology solutions that improve patient outcomes while helping increase facility revenue.
  • Thynk Health is on a mission to save lives lost to lung cancer by disrupting outdated, burdensome lung cancer screening processes.
  • Thynk Health's platform optimizes data-driven workflows and provides operational and clinical analytics for cancer screening programs and incidental findings management.

Exact Sciences schedules second quarter 2021 earnings call

Retrieved on: 
Thursday, July 8, 2021
Branches of biology, Medicine, Medical specialties, Medical genetics, Medical terminology, Exact Sciences, Medical tests, Cancer screening, Medical diagnosis, Screening

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.

Key Points: 
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • Exact Sciences unites visionary collaborators to help advance the fight against cancer.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Cancer and Blood Specialty Clinic Adopts Deep Lens’ Clinical Trial Matching Solution VIPER™ to Broaden Clinical Research Program

Retrieved on: 
Wednesday, July 7, 2021
Data management, Other Health, Technology, Pharmaceutical, Practice Management, Oncology, Managed care, Hospitals, Clinical trials, Science, Biotechnology, Software, Other Science, Health, Research, Medicine, Cancer, Screening, Health, Clinical medicine, Oncology, the Cancer and Blood Specialty Clinic, Deep Lens, THE CANCER AND BLOOD SPECIALTY CLINIC, DEEP LENS

The Cancer and Blood Specialty Clinic (CBSC) and Deep Lens announced today that they have entered into a strategic partnership to integrate artificial intelligence (AI)-based clinical trial matching solution, VIPER, into the Southern California-based practice.

Key Points: 
  • The Cancer and Blood Specialty Clinic (CBSC) and Deep Lens announced today that they have entered into a strategic partnership to integrate artificial intelligence (AI)-based clinical trial matching solution, VIPER, into the Southern California-based practice.
  • The majority of cancer patients are diagnosed and treated at community oncology practices, like the Cancer and Blood Specialty Clinic.
  • Like the Cancer and Blood Specialty Clinic, any practice that utilizes CureMD can easily integrate VIPER and all other Deep Lens screening services free of charge.
  • Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.

Global High Content Screening Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts

Retrieved on: 
Friday, July 2, 2021
Natural sciences, Physical sciences, Drug discovery, Chemistry, Microscopy, Laboratory techniques, High-content screening, Medical tests, Screening, Markets.com, HCS, Cellomics

DUBLIN, July 2, 2021 /PRNewswire/ -- The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 2, 2021 /PRNewswire/ -- The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • High content screening (HCS), or high content analysis, refers to an analytical method of automated microscopy that uses visualization tools to obtain quantitative data from cell populations.
  • What has been the impact of COVID-19 on the global high content screening market?
  • What is the structure of the global high content screening market and who are the key players?

Insights on the High Content Screening Global Market to 2026 - by Product, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Research, Science, Academic disciplines, Natural sciences, Physical sciences, Drug discovery, High-content screening, Microscopy, Laboratory techniques, Screening, Compound annual growth rate

The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global high content screening market exhibited strong growth during 2015-2020.
  • Looking forward, the publisher expects the market to grow at a CAGR of 8.2% during 2021-2026.
  • High content screening (HCS), or high content analysis, refers to an analytical method of automated microscopy that uses visualization tools to obtain quantitative data from cell populations.

Olympus Supports New Recommendation to Begin Colorectal Cancer Screenings at Age 45

Retrieved on: 
Thursday, July 1, 2021
Medicine, Clinical medicine, Health, Diagnostic gastroenterology, Colorectal cancer, Cancer screening, Medical terminology, Prevention, Colonoscopy, United States Preventive Services Task Force, Cancer, Screening

CENTER VALLEY, Pa., July 1, 2021 /PRNewswire/ -- Today, Olympus announced its support of the new recommendation issued by the United States Preventive Services Task Force (USPSTF) to begin colorectal cancer screenings for all individuals beginning at age 45.

Key Points: 
  • CENTER VALLEY, Pa., July 1, 2021 /PRNewswire/ -- Today, Olympus announced its support of the new recommendation issued by the United States Preventive Services Task Force (USPSTF) to begin colorectal cancer screenings for all individuals beginning at age 45.
  • Age is one of the most prominent risk factors of colorectal cancer, with 94% of cases found in those who are 45 years or older.
  • "This cause is meaningful to Olympus as the pioneering manufacturer of endoscopic devices used to detect and treat colorectal cancer, and it's very meaningful to me personally as I lost my father to colorectal cancer.
  • Research shows that this new age recommendation is important for all, but crucial for Black individuals because early onset colorectal cancer is much more common.6
    To learn more about colorectal cancer and screenings, visit Colonoscopy Today .